NEW HAVEN, Conn., Dec. 03, 2018 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference being held December 12, 2018 in New York, NY.
| Details of the Conference: | |||
| Event: | BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference | ||
| Date: | December 12, 2018 | ||
| Time: | 10:20 AM ET | ||
A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for 30 days. In addition to his presentation, Dr. Mehta will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with BTI management should contact their BMO representative.
About BXCL501:
BXCL501 is a first in class, sublingual film of dexmedetomidine, a selective alpha 2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and has demonstrated anti-agitation effects in preclinical and clinical studies. It has a well-established regulatory and reimbursement path in schizophrenia and bipolar disorder, as demonstrated by a previously-approved drug, Adasuve.
About BXCL701:
BXCL701 is an orally-available systemic innate-immune activator with dual mechanisms of action. It has demonstrated single agent activity in melanoma, with an established safety profile from 700 healthy subjects and cancer patients. Designed to stimulate both the innate and acquired immune systems, BXCL701 works by inhibiting dipeptidyl peptidase (DPP) 8/9 and blocking immune evasion by targeting Fibroblast Activation Protein (FAP). Preclinical combination data evaluating BXCL701, a checkpoint inhibitor and other immuno-oncology agents has demonstrated encouraging anti-tumor activity in multiple tumor types and formation of functional immunological memory. BXCL701’s primary mechanism of action has recently been highlighted in multiple peer reviewed journals, providing an important validation of the scientific rationale behind BXCL701.
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
The Ruth Group
Lee Roth/ Janhavi Mohite
646-536-7012/7026
[email protected]/ [email protected]
